P-glycoprotein expression in cartilaginous tumors

Journal of Surgical Oncology

Volumn 65, Issue 2, 1997, Pages 95-105

  Rosier, Randyn ^a   O'Keefe, Regis J ^a   Teot, Lisa A ^a   Fox, Edward J ^a   Nester, Theresa A ^a   Puzas, J Edward ^a   Reynolds, Paul R ^a   Hicks, David G ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Cartilage; Chondrosarcoma; MDR I; P glycoprotein; Sarcoma

Indexed keywords

GLYCOPROTEIN P;

ARTICLE; CARTILAGE TUMOR; CHONDROSARCOMA; CONTROLLED STUDY; DNA PROBE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MULTIDRUG RESISTANCE; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA;

ADULT; BONE NEOPLASMS; CARTILAGE; CARTILAGE DISEASES; CHONDROSARCOMA; FEMALE; GENES, MDR; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE PROBES; OSTEOCHONDROMA; P-GLYCOPROTEIN; PARAFFIN EMBEDDING; RETROSPECTIVE STUDIES;

EID: 0030795971     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199706)65:2<95::AID-JSO5>3.0.CO;2-I     Document Type: Article

References (58)

1. Lichtenstein L, Jaffe HL: Chondrosarcoma of bone. Am J Pathol 1943;19:553-589.
2. Huvos AG, Marcove RC: Chondrosarcoma in the young: A clinicopathologic analysis of 79 patients younger than 21 years of age. Am J Surg Pathol 1987;11:930-942.
3. Bogumill GP, Schwamm HR: "Orthopedic Pathology: A Synopsis with Clinical and Radiographic Correlation." Philadelphia: Saunders, 1984, pp 414-436.
4. Greenspan A: Tumors of cartilage origin. Ortho Clin North Am 1989;20:347-366.
5. Evans HL, Ayala AG, Romsdahl MM: Prognostic factors in chondrosarcoma of bone: A clinicopathologic analysis with emphasis on histologic grading. Cancer 1977;40:818-831.
6. Sanerkin NG, Gallagher P: A review of the behavior of chondrosarcoma of bone. J Bone Joint Surg 1979;61B:395-400.
7. Pritchard DJ, Lunke RJ, Taylor WF, Dahlin DC, Medley BE: Chondrosarcoma: A clinicopathologic and statistical analysis. Cancer 1980;45:149-157.
8. Reid R: New developments in the diagnosis of chondrosarcoma. J Pathol 1991;163:93-94.
9. Mirra JM, Gold R, Downs J, Eckardt JJ: A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones: A clinicopathologic analysis of 51 cases. Clin Orthop 1985;201:214-237.
10. Schiller AL: Diagnosis of borderline cartilage lesions of bone. Semin Diag Pathol 1985;2:45-62.
11. Tsuchiya H, Ueda Y, Morishita H, et al.: Borderline chondrosarcoma of long and flat bones. J Cancer Res Clin Oncol 1993;119: 363.
12. Lewis MM: An approach to the treatment of malignant bone tumors. Orthopaedics 1985;8:655-656.
13. Sundaram M, McGuire MH, Herbold DR, et al.: Magnetic resonance imaging in planning limb-salvage surgery for primary malignant tumors of bone. J Bone Joint Surg 1986;68A:809-819.
14. Burt M, Fulton M, Wessner-Dunlap S, et al.: Primary bony and cartilaginous sarcomas of chest wall: results of therapy. Ann Thorac Surg 1992;54:226.
15. Harwood AR, Krajbich JI, Fornasier VL: Radiotherapy of chondrosarcoma of bone. Cancer 1980;45:2769-2777.
16. Ling V: P-glycoprotein mediated multi-drug resistance to cancer chemotherapy. Adv Oncol 1993;9:3-9.
17. Weinstein RS, Kuszak JR, Kluskens LF, Coon JS: P-glycoproteins in pathology: the multidrug resistance gene family in humans. Hum Pathol 1990;21:34-48.
18. Goldstein LJ, Galski H, Fojo A, et al.: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81: 116-124.
19. Herweijer H, Sonnevek P, Baas F, Nooter K: Expression of mdr1 and mdr3 multidrug resistance genes in human acute and chronic leukemias with stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst 1990;82:1133-1140.
20. Kaye SB, Kerr DJ: Multidrug resistance: Clinical relevance in haematological malignancies. Blood Rev 1991;5:38-41.
21. Chan HSL, Thorner PS, Haddard G, Ling V: Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990;8:689-704.
22. Gerlach JH, Bell DR, Karakousis C, et al.: P-glycoprotein in human sarcoma: Evidence for multidrug resistance. J Clin Oncol 1987;5:1452-1460.
23. Garberoglio C, Dudas M, Casper ES, et al.: Expression of P-glycoprotein in normal muscle cells and myogenic tumors. Arch Pathol Lab Med 1992;116:1055-1061.
24. Chan HSL, Haddad G, Thomer PS. et al.: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991;325:1604-1614.
25. Wunder JS, Bell RS, Wold L, Andrulis IL: Expression of the multidrug resistance gene in osteosarcoma: a pilot study. J Ortho Res 1993;11:396-403.
26. Rosier RN, Teot LA, Hicks DG, et al.: Multiple drug resistance in osteosarcoma. Iowa Orthop J 1995;15:66-73.
27. Bramlett C, Lennington W: P-glycoprotein expression in primary osseous neoplasms. Mod Pathol 1993;6:5A.
28. Goasquen JE, Dossot JN, Fardel D, et al.: Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: Prognostic implications. Blood 1993;81:2394-2398.
29. Kuo MT, Zhao JY, Teeter LD, et al.: Activation of multidrug resistance (p glycoprotein) mdr3/mdr1a gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell Growth Differ 1992;3:531-540.
30. Schinkel AH, Roelofs EM, Borst P: Characterization of the human MDR3 P-glycoprotein and its recognition of P-glycoprotein-specific antibodies. Cancer Res 1991;51:2628-2635.
31. Georges E, Bradley G, Gariepy J, Ling V: Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci USA 1990;87:152-156.
32. Toth K, Vaughan MM, Slocum HK, et al.: New immunohistochemical "sandwich" staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed paraffin-embedded human tissues. Am J Pathol 1994;144:227-236.
33. Crabb ID, Hughes SS, Hicks DG, et al.: Nonradioactive in situ hybridization using digoxigenin labeled oligonucleotides: applications to musculoskeletal tissues. Am J Pathol 1992;141:579-589.
34. Hsu S, Raine L, Fanger H: Use of avadin-biotin-peroxidase complex in immunoperoxidase techniques. J Histochem Cytochem 1981;29:577-580.
35. Shi Z-R, Itkowitz SH, Kim YS: A comparison of three immunoperoxidase techniques for antigen detection in colorectal carcinoma tissues. J Histochem Cytochem 1988;36:317-322.
36. Weinstein RS, Coon JS: Laboratory assessment of P-glycoprotein in cancer chemosensitivity testing. Hum Pathol 1990;21:785-786.
37. Nakashima Y, Unni KK, Shives TC, et al.: Mesenchymal chondrosarcoma of bone and soft tissue: a review of 111 cases. Cancer 1986;57:2444-2453.
38. Marcove RC, Mike V, Hutter RP, et al.: Chondrosarcoma of the pelvis and upper end of the femur: an analysis of factors influencing survival time in one hundred and thirteen cases. J Bone Joint Surg 1972;54A:561-572.
39. Gros P, Croop J, Housman D: Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 1986;47:371-380.
40. Schrenk D, Gant TW, Preisegger KH, et al.: Induction of multidrug resistance gene expression during cholestasis in rats and nonhuman primates. Hepatology 1993;17:854-860.
41. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 1993; 62:395-427.
42. Kramer R, Wever TK, Morse B, et al.: Constitutive expression of multidrug resistance in human colorectal tumours and cell lines. Br J Cancer 1993;67:959-968.
43. Nishiyama K, Shirahama T, Yoshimura A, et al.: Expression of the multidrug transporter, P-glycoprotein in renal and transitional cell carcinomas. Cancer 1993;71:3611-3619.
44. Mangham DC, Cannon A, Komiya S, et al.: P-glycoprotein is expressed in the mineralizing regions of the skeleton. Calcif Tissue Int 1996;58:186-191.
45. Schott B, Londos-Gagliardi D, Ries C, et al.: Pharmacological and molecular characterization of intrinsic and acquired doxorubicin resistance in murine tumor cell lines. J Cancer Res Clin Oncol 1993;119:527-532.
46. Serra M, Scotlandi K, Manara MC, et al.: Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. Anticancer Res 1993;13:323-329.
47. Chaudhary PM, Roninson IB: Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993;85:632-639.
48. Cordon-Cardo C, O'Brien JP, Boccia J, et al.: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990;38:1277-1287.
49. Vola M: P-glycoprotein associated expression of c-fos and c-jun products in human lung carcinomas. Anticancer Res 1993;13: 375-378.
50. Vola M, Kastel M, Mattern J, Efferth T: Expression of resistance factors (P-glycoprotein, glutathione S-transferase, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer 1993;71:3981-3987.
51. Bhushan A, Abramson R, Chiu JF, Tritton TR: Expression of c-fos in human and murine multidrug-resistant cells. Mol Pharmacol 1992;42:69-74.
52. Sandberg M, Vuorio T, Hirvonen H, et al.: Enhanced expression of TGF-β and c-fos mRNAs in the growth plates of developing human long bones. Development 1988;102:461-470.
53. Ruther U, Komitowski D, Schubert FR, Wagner EF: c-fos expression induces bone tumors in transgenic mice. Oncogene 1989;4: 861-865.
54. Rao VV, Anthony DC, Piwnica-Worms D: MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Res 1994;54:1536-1541.
55. Currier SJ, Kane SE, Willingham MC, et al.: Identification of residues in the first cytoplasmic loop of P-glycoprotein involved in the function of chimeric human MDR-1-MDR-2 transporters. J Biol Chem 1992;267:25153-25159.
56. Miller TP, Grogan TM, Dalton WS, et al.: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Onc 1991;9:17-24.
57. Van de Vrie W, Gheuvens EE, Durante NH, et al.: In vitro and in vivo chemosensitizing effect of cyclosporine A on an intrinsic multidrug-resistant rat colon tumour. J Cancer Res Clin Oncol 1993;119:609-614.
58. Keller RP, Altermatt HJ, Nooter K, et al.: SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoportein-mediated multidrug resistance of murine leukemia. Int J Cancer 1992;50:593-597.